A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
Observational studyAges 18–74United Kingdom + United StatesDepression
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarity
Things to check before joining
Study start dateStarted: October 26, 2021
Recruitment status
Terminated
Enrollment listed in the registry
7
Sponsor
Janssen Research & Development, LLC
Sponsor type
Other organization
Study type
Observational
Intervention type
OTHER
Study phase
Not clearly listed
Locations
United States, United Kingdom
Age range
From 18 Years to 74 Years
Official registry ID
NCT05109195
Official title
Show the full official title
A Prospective, Observational Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake /Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant as a Control Arm for the Safety Assessments in the Seltorexant Phase 3 Program
Questions about this study?
The HopeStage team will email you.
Recruitment & locations
Terminated
San Francisco, United States · Boston, United States · Pittsburgh, United States
1 more locations
Oxford, United Kingdom
A listed location does not confirm current availability.
FAQ
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Who can participate?
Listed age limits: 18 years to 74 years.
Is this study still recruiting?
The registry lists this study as terminated.
Explore other studies
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.